BioCentury | Jul 6, 2017
Company News

Pulmatrix gets portfolio of kinase inhibitors from RespiVert

...in Phase I testing and Pulmatrix expects "to quickly move to clinical proof-of concept studies." RespiVert...
BioCentury | Mar 25, 2017
Finance

Respiratory redux

...SR One. Six of Pulmocide’s seven-member management team held the same roles at pulmonary company RespiVert Ltd....
...RespiVert in 2010 for an undisclosed sum. Pulmocide also has three investors in common with RespiVert...
BioCentury | Oct 17, 2016
Clinical News

rectal TOP1288: Phase IIa started

...60 patients with moderate to severe disease activity. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | Mar 28, 2016
Product Development

Accelerating the Accelerator

...the immunology therapeutic area at Janssen. Prior to that, he was head of biology for RespiVert Ltd....
BioCentury | Mar 28, 2016
Clinical News

TOP1288: Phase I data

...I trial evaluating an oral formulation of TOP1288. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | May 25, 2015
Clinical News

TOP1288: Phase I started

...in healthy volunteers and multiple doses in patients. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | Nov 21, 2013
Financial News

Pulmocide raises L17 million in series A

...Maina Bhaman joined Pulmocide's board. Pulmocide CEO Garth Rapeport and CSO Pete Strong previously co-founded RespiVert Ltd....
BioCentury | Apr 16, 2012
Company News

SkyePharma, J&J deal

...SkyePharma partnered with RespiVert Ltd. to conduct a feasibility study to develop a dry powder inhaler dosage...
...conduct a feasibility study to develop a dry powder inhaler dosage form for an undisclosed RespiVert...
...feasibility work over the past 15 months on another RespiVert compound for the same indication. RespiVert...
BioCentury | Dec 12, 2011
Company News

TopiVert, J&J deal

...TopiVert partnered with RespiVert Ltd. to discover and develop narrow-spectrum kinase inhibitors using IP from RespiVert, which...
...receive exclusive rights to select and develop compounds for ophthalmic and gastrointestinal inflammatory diseases, while RespiVert...
BioCentury | Dec 7, 2011
Financial News

TopiVert debuts with $12.5 million

...eye and gut. TopiVert partnered with RespiVert Ltd. to discover and develop narrow-spectrum kinase inhibitors using RespiVert's...
...receive exclusive rights to select and develop compounds for ophthalmic and gastrointestinal inflammatory diseases, while RespiVert...
...Maina Bhaman joined TopiVert's board. Imperial Innovations and SV Life Sciences also were investors in RespiVert...
Items per page:
1 - 10 of 17
BioCentury | Jul 6, 2017
Company News

Pulmatrix gets portfolio of kinase inhibitors from RespiVert

...in Phase I testing and Pulmatrix expects "to quickly move to clinical proof-of concept studies." RespiVert...
BioCentury | Mar 25, 2017
Finance

Respiratory redux

...SR One. Six of Pulmocide’s seven-member management team held the same roles at pulmonary company RespiVert Ltd....
...RespiVert in 2010 for an undisclosed sum. Pulmocide also has three investors in common with RespiVert...
BioCentury | Oct 17, 2016
Clinical News

rectal TOP1288: Phase IIa started

...60 patients with moderate to severe disease activity. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | Mar 28, 2016
Product Development

Accelerating the Accelerator

...the immunology therapeutic area at Janssen. Prior to that, he was head of biology for RespiVert Ltd....
BioCentury | Mar 28, 2016
Clinical News

TOP1288: Phase I data

...I trial evaluating an oral formulation of TOP1288. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | May 25, 2015
Clinical News

TOP1288: Phase I started

...in healthy volunteers and multiple doses in patients. TopiVert licensed narrow-spectrum kinase inhibitor-related IP from RespiVert Ltd....
BioCentury | Nov 21, 2013
Financial News

Pulmocide raises L17 million in series A

...Maina Bhaman joined Pulmocide's board. Pulmocide CEO Garth Rapeport and CSO Pete Strong previously co-founded RespiVert Ltd....
BioCentury | Apr 16, 2012
Company News

SkyePharma, J&J deal

...SkyePharma partnered with RespiVert Ltd. to conduct a feasibility study to develop a dry powder inhaler dosage...
...conduct a feasibility study to develop a dry powder inhaler dosage form for an undisclosed RespiVert...
...feasibility work over the past 15 months on another RespiVert compound for the same indication. RespiVert...
BioCentury | Dec 12, 2011
Company News

TopiVert, J&J deal

...TopiVert partnered with RespiVert Ltd. to discover and develop narrow-spectrum kinase inhibitors using IP from RespiVert, which...
...receive exclusive rights to select and develop compounds for ophthalmic and gastrointestinal inflammatory diseases, while RespiVert...
BioCentury | Dec 7, 2011
Financial News

TopiVert debuts with $12.5 million

...eye and gut. TopiVert partnered with RespiVert Ltd. to discover and develop narrow-spectrum kinase inhibitors using RespiVert's...
...receive exclusive rights to select and develop compounds for ophthalmic and gastrointestinal inflammatory diseases, while RespiVert...
...Maina Bhaman joined TopiVert's board. Imperial Innovations and SV Life Sciences also were investors in RespiVert...
Items per page:
1 - 10 of 17